section name header

Pronunciation ⬇

sil-OS-tah-zol

Classifications ⬆ ⬇

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: platelet aggregation inhibitors

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Inhibits the enzyme cyclic adenosine monophosphate (cAMP) phosphodiesterase III (PDE III), which results in increased cAMP in platelets and blood vessels, producing inhibition of platelet aggregation and vasodilation.
Therapeutic effects:
  • Reduced symptoms of intermittent claudication with improved walking distance.

Pharmacokinetics ⬆ ⬇

Absorption: Slowly absorbed after oral administration.

Distribution: Unknown.

Protein Binding: 95–98% bound to plasma proteins; one active metabolite is 97.4% bound, the other is 66% bound.

Metabolism/Excretion: Extensively metabolized by the liver, two metabolites have platelet aggregation inhibitory activity; metabolites are mostly excreted by the kidneys.

Half-Life: Cilostazol and its active metabolites: 11–13 hr.

Time/Action Profile ⬆ ⬇

(symptom reduction)

ROUTEONSETPEAKDURATION
PO2–4 wkup to 12 wkunknown



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypotension, left ventricular outflow obstruction, palpitations, tachycardia

GI: diarrhea

Neuro: headache, dizziness

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Pletal

Code ⬆

NDC Code